In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Commentary|Videos|June 12, 2025
Allogeneic Transplant and Gene Therapy in Sickle Cell Disease
Author(s)Markus Y. Mapara, MD, PhD
Markus Y. Mapara, MD, PhD, of Columbia University Irving Cancer Center, discusses the use of allogeneic transplant and gene therapy for patients with sickle cell disease.
Advertisement
Markus Y. Mapara, MD, PhD, of Columbia University Irving Cancer Center, discusses the use of allogeneic transplant and gene therapy for patients with sickle cell disease.
Advertisement
Related to this article
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
A rituximab biosimilar has been approved by the FDA.
Shorter treatments of venetoclax plus azacitidine did not meet similarity criteria for longer treatments in the OPTI-AML trial.
The FDA has granted orphan drug designation to enzomenib for acute lymphoblastic leukemia.
FDA has granted RMAT and fast track designations to cema-cel as a frontline consolidation in large B-cell lymphoma.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
Advertisement
Advertisement
Trending on OncLive
1
FDA Issues CRL to 177Lu-Edotreotide for GEP-NETs
2
SYNC-T Therapy SV-102 Shows Early Promise, Advances to Phase 2 LEGION-100 Trial in Refractory Prostate Cancer
3
Divesiran Meets Primary Response End Point in Phlebotomy-Dependent Polycythemia Vera
4
Early mRNA Vaccine Data Excite Possibilities of Long-Term PDAC Remissions
5